Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono to publish new MS drug data at AAN conference

Merck Serono to publish new MS drug data at AAN conference

11th April 2011

Merck Serono is attending a medical conference being held by the American Academy of Neurology (AAN), where it is publishing new clinical data on various multiple sclerosis (MS) treatments.

During the AAN annual meeting taking place in Hawaii this month, the company is presenting data on established and forthcoming MS therapy options such as Rebif, RebiSmart and Cladribine Tablets.

This will include results from a phase III study of different Rebif dosing frequencies and data from various Cladribine trials highlighting its safety and efficacy among different patient groups.

Dr Bernhard Kirschbaum, Merck Serono's head of global research and development, said this information will help to enhance understanding of the drugs' performance and clinical effects.

"We are committed to providing treatments that meet the individual needs of people living with multiple sclerosis at the various stages of the disease," he added.

Earlier this month, the company agreed to license two of its promising central nervous system disease treatments, pruvanserin and sarizotan, to partner Newron Pharmaceuticals as part of an ongoing collaboration.ADNFCR-8000103-ID-800494410-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.